Sophia Genetics Sa ( (SOPH) ) has released its Q1 earnings. Here is a breakdown of the information Sophia Genetics Sa presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SOPHiA GENETICS is a cloud-native healthcare technology company specializing in data-driven medicine, using AI to provide insights for cancer and rare disorder treatments globally. In its first quarter of 2025, SOPHiA GENETICS reported a revenue increase of 13% year-over-year, reaching $17.8 million, with a gross margin improvement to 68.7%. Despite a net loss increase to $17.4 million, the adjusted EBITDA loss improved by 24% to $9.8 million, reflecting effective cost management. The company expanded its customer base, landing 28 new core genomics customers and achieving significant growth in the U.S. market, with over 30% revenue growth from core genomics customers. Looking forward, SOPHiA GENETICS maintains its revenue guidance for 2025 between $72 million and $76 million and aims to approach adjusted EBITDA breakeven by the end of 2026, with positive adjusted EBITDA expected in the second half of 2027.